QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.088146v1 315/1/196    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamprecht, A. Articles by Kawashima, Y. Search for Related Content PubMed PubMed Citation Articles by Lamprecht, A. Articles by Kawashima, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

INFLAMMATION AND IMMUNOPHARMACOLOGY

Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats

Laboratory of Biopharmaceutics and Pharmaceutical Engineering, University of Franche-Comté, Besançon, France (A.L.); and Laboratory of Pharmaceutical Engineering, Gifu Pharmaceutical University, Gifu, Japan (H.Y., H.T., Y.K.)

Nanoparticles (NP) are proposed for targeted drug delivery to the inflammation site in severe cases of inflammatory bowel disease where state-of-the-art delivery devices fail. FK506 (tacrolimus) entrapped into NP was administered either orally or rectally to male Wistar rats suffering from a preexisting experimental colitis. Clinical activity score, colon/body weight index, and myeloperoxidase activity were determined to assess the inflammation. Tissue penetration experiments elucidated the processes involved in the proposed new therapeutic approach. The therapeutic effects of FK506 solutions as well as FK506-NP by oral route were minor. The myeloperoxidase activity and colon/body weight ratio decreased significantly (P < 0.05) only after the rectal administration of FK506-NP, whereas treatment by free drug was not different from colitis control in both 2,4,6-trinitrobenzenesulfonic acid and oxazolone colitis model. NP allows an enhanced and selective drug penetration into the inflammation site as opposed to surrounding healthy tissue (healthy: FK506, 109 ± 18 nmol/cm²; FK506-NP, 51 ± 13 nmol/cm²; colitis: FK506, 79 ± 28 nmol/cm²; FK506-NP, 105 ± 24 nmol/cm²), presumably by protecting the encapsulated drug against influences from efflux systems and mucosal metabolism. The relative drug penetration into the inflamed tissue is about 3-fold higher compared with healthy tissue when using NP as drug carriers. The use of drug-loaded NP offers several advantages compared with standard therapeutic strategies such as a higher selectivity in adhesion to and enhanced drug penetration into the inflamed tissue.

Address correspondence to: Dr. Alf Lamprecht, EA 3924, Faculty of Medicine and Pharmacy, Place Saint Jacques, 25030 Besançon Cedex, France. E-mail: alf.lamprecht{at}pharma.uhp-nancy.fr

This article has been cited by other articles:

				Y. Pellequer, Y. Meissner, N. Ubrich, and A. Lamprecht Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 726 - 733. [Abstract] [Full Text] [PDF]

				D. M. Shin Nanotechnology: A Novel Approach to Drug Delivery in Cancer Therapeutics Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 3 - 8. [Full Text] [PDF]

				R. Sinha, G. J. Kim, S. Nie, and D. M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., August 1, 2006; 5(8): 1909 - 1917. [Abstract] [Full Text] [PDF]

				H. L. Wong, R. Bendayan, A. M. Rauth, H. Y. Xue, K. Babakhanian, and X. Y. Wu A Mechanistic Study of Enhanced Doxorubicin Uptake and Retention in Multidrug Resistant Breast Cancer Cells Using a Polymer-Lipid Hybrid Nanoparticle System J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1372 - 1381. [Abstract] [Full Text] [PDF]